CSF2 and rheumatoid arthritis: Amongst patients with rheumatoid arthritis who fail to respond to ‘traditional’ nonbiological DMARDs these pathways clearly remain important drivers of disease for many, and GM-CSF blockade has now joined the above strategies as a rapidly effective treatment modality in this setting [36].